THE ROLE OF MICRORNA-346 IN PROSTATE CANCER PROGRESSION: CLINICAL SIGNIFICANCE AND BIOMARKER POTENTIAL
Abstract
Objective: The aim of this study was to analyze the expression changes and clinical significance of microRNA-346 (MiRNA-346) in PCa genesis, development and hormone resistance transformation.
Method: Data of the middle-aged and elderly male patients who were treated in Tengzhou Central People’s Hospital from January 2017 to December 2023 were collected. The tissues and corresponding preoperative serum of 128 patients with newly diagnosed PCa and 130 patients with benign prostatic hyperplasia (BPH), 120 patients with hormone-sensitive PCa (HSPC), 116 patients with castration-resistant PCa (CRPC), and 150 healthy males of the same age who underwent physical examination in the physical examination center of our hospital were collected. Quantitative real-time polymerase chain reaction was used to detect the relative expression of miRNA-346 in the tissues and serum of the subjects. GraphPad Prism statistical analysis software was utilized to analyze the expression changes of miRNA-346 in the occurrence and progression of PCa and its correlation with clinical and pathological features.
Result: The expression of miRNA-346 was significantly lower in PCa patients than in BPH patients and healthy population (P<0.001), while there was no difference between BPH and healthy population (P=0.516). Tissue and serum expression were positively correlated (P<0.001). miRNA-346 was negatively correlated with tPSA, PHI, clinical stage, and Gleason score in PCa tissue/serum (P<0.001). Serum miRNA-346 in CRPC patients was negatively correlated with time to transformation (r=0.6575) and survival (r=0.5699) (P<0.001). Serum miRNA-346 was positively correlated with tPSA and ALP in HSPC and CRPC patients (P<0.001).
Conclusion: Serum miRNA-346 expression in the process of hormone resistance conversion in PCa is gradually increasing, making it a potential biomarker for monitoring PCa progression.
Copyright (c) 2025 Lei Wang, Yanqing Wang, Li Tian, Zhengwei Wang, Xiaoqiang Liu, Guangzhou Chen
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.